Skip to content

Clinical trials

Multiple Sclerosis, Relapsing-Remitting trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Sclerosis, Relapsing-Remitting Phase: Not applicable Country / region: United States Clear all

38 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20061
20101
20121
20134
20141
20151
20161
20172
20184
20191
20201
20223
20235
20242
20253
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed18
Recruiting9
Active, not recruiting4
Not yet recruiting2
Withdrawn2
Unknown status2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shirley Ryan AbilityLab4
Terry L. Wahls4
Johns Hopkins University3
University of Alabama at Birmingham3
University of Missouri, Kansas City2
Amanda Irish1
Cionic, Inc.1
George Washington University1
Georgia State University1
Icahn School of Medicine at Mount Sinai1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Sclerosis, Relapsing-Remitting38
Multiple Sclerosis20
Multiple Sclerosis, Chronic Progressive7
Fatigue6
Hypoxia3
Ataxia1
Autoimmune Diseases of the Nervous System1
Cognitive Dysfunction1
Demyelinating Autoimmune Diseases, CNS1
Demyelinating Diseases1

Trials

Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.